JP2002535360A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002535360A5 JP2002535360A5 JP2000595674A JP2000595674A JP2002535360A5 JP 2002535360 A5 JP2002535360 A5 JP 2002535360A5 JP 2000595674 A JP2000595674 A JP 2000595674A JP 2000595674 A JP2000595674 A JP 2000595674A JP 2002535360 A5 JP2002535360 A5 JP 2002535360A5
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- alkyl
- aryl
- compound
- independently selected
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 description 16
- 239000001257 hydrogen Substances 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 13
- 125000000217 alkyl group Chemical group 0.000 description 11
- 125000003118 aryl group Chemical group 0.000 description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 2
- 230000024587 synaptic transmission, glutamatergic Effects 0.000 description 2
- LAGRSZUHYGUEDR-UHFFFAOYSA-N (2-phenyl-2-adamantyl)methanamine Chemical group C1C2CC(C3)CC1CC3C2(CN)C1=CC=CC=C1 LAGRSZUHYGUEDR-UHFFFAOYSA-N 0.000 description 1
- -1 3-ethylphenyl Chemical group 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- XZZMRWKMFHHUCE-UHFFFAOYSA-N [2-(3-ethylphenyl)-2-adamantyl]methanamine Chemical compound CCC1=CC=CC(C2(CN)C3CC4CC(C3)CC2C4)=C1 XZZMRWKMFHHUCE-UHFFFAOYSA-N 0.000 description 1
- UOQAPRSNEKTPDA-UHFFFAOYSA-N [2-(3-methylphenyl)-2-adamantyl]methanamine Chemical compound CC1=CC=CC(C2(CN)C3CC4CC(C3)CC2C4)=C1 UOQAPRSNEKTPDA-UHFFFAOYSA-N 0.000 description 1
- CYAUNWPGALMQFI-UHFFFAOYSA-N [2-(4-methylphenyl)-2-adamantyl]methanamine Chemical compound C1=CC(C)=CC=C1C1(CN)C(C2)CC3CC2CC1C3 CYAUNWPGALMQFI-UHFFFAOYSA-N 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 125000000040 m-tolyl group Chemical group [H]C1=C([H])C(*)=C([H])C(=C1[H])C([H])([H])[H] 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9901691.7A GB9901691D0 (en) | 1999-01-26 | 1999-01-26 | Chemical compounds |
| GB9901691.7 | 1999-01-26 | ||
| PCT/GB2000/000207 WO2000044371A1 (en) | 1999-01-26 | 2000-01-26 | 2-adamantanemethanamine compounds for treating abnormalities in glutamatergic transmission |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002535360A JP2002535360A (ja) | 2002-10-22 |
| JP2002535360A5 true JP2002535360A5 (enExample) | 2007-03-08 |
Family
ID=10846525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000595674A Pending JP2002535360A (ja) | 1999-01-26 | 2000-01-26 | グルタメート作用性伝達における異常を処置するための２−アダマンタンメタンアミン化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6531511B1 (enExample) |
| EP (1) | EP1143964B1 (enExample) |
| JP (1) | JP2002535360A (enExample) |
| AT (1) | ATE262326T1 (enExample) |
| AU (1) | AU2116900A (enExample) |
| CA (1) | CA2360674A1 (enExample) |
| DE (1) | DE60009263T2 (enExample) |
| ES (1) | ES2216852T3 (enExample) |
| GB (1) | GB9901691D0 (enExample) |
| WO (1) | WO2000044371A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0018272D0 (en) * | 2000-07-25 | 2000-09-13 | Vernalis Research Limited | Chemical compounds IV |
| ES2357808T3 (es) | 2001-06-07 | 2011-04-29 | Christine Dr. Sang | Tratamiento del dolor neuropático con antagonistas del receptor de n-metil-d-aspartato (nmda). |
| US7283414B1 (en) * | 2006-05-24 | 2007-10-16 | Sandisk 3D Llc | Method for improving the precision of a temperature-sensor circuit |
| WO2008035049A1 (en) * | 2006-09-18 | 2008-03-27 | Merz Pharma Gmbh & Co. Kgaa | Adamantanyl-(cyclopropyl)-ketones as metabotropic glutamate receptor modulators |
| ES2341517B1 (es) * | 2008-03-28 | 2011-01-25 | Farmalider, S.A | Utilizacion de un compuesto inhibidor de la activacion de la enzima erk 1/2 en el tratamiento de enfermedades neurodegenerativas. |
| WO2011147999A1 (es) | 2010-05-24 | 2011-12-01 | Farmalider, S.A. | Compuesto inhibidor de la activación de la enzima erk1/2 para su uso en el tratamiento de enfermedades neurodegenerativas |
| EP3643703A4 (en) | 2017-06-21 | 2020-12-23 | Daiichi Sankyo Co., Ltd. | EP300 / CREBBP INHIBITOR |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL6804065A (enExample) * | 1968-03-22 | 1969-09-24 | ||
| YU36365B (en) * | 1974-05-16 | 1983-06-30 | Pliva Pharm & Chem Works | Process for preparing alpha-amino-2-adamantyl acetic acid |
| YU30589A (en) * | 1989-02-09 | 1991-10-31 | Imunoloski Z Zagreb | New adamantyl containing tripeptides and it's hydrochloride and process for preparing and use |
| US5334618A (en) * | 1991-04-04 | 1994-08-02 | The Children's Medical Center Corporation | Method of preventing NMDA receptor-mediated neuronal damage |
| WO1992017168A1 (en) * | 1991-04-04 | 1992-10-15 | The Children's Medical Center Corporation | Method of preventing nmda receptor-mediated neuronal damage |
| US6011155A (en) | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
| GB9726388D0 (en) | 1997-12-12 | 1998-02-11 | Cerebrus Ltd | Chemical compounds |
| US6008240A (en) | 1997-12-15 | 1999-12-28 | Gliatech, Inc. | 2-(1H-4(5)-imidazoyl) cyclopropyl derivatives |
| TR200001795T2 (tr) | 1997-12-16 | 2000-11-21 | Warner-Lambert Company | 1-İkameli-1-Aminometil-sikloalkan türevleri (=Gabapentin analogları), bunların hazırlanması ve nörolojik bozuklukların tedavisinde kullanımı. |
| GB9802225D0 (en) | 1998-02-02 | 1998-04-01 | Cerebrus Ltd | Chemical compounds |
| BR0013143A (pt) | 1999-08-12 | 2002-06-11 | Pharmacia Italia Spa | Derivados de 3 (5) amino pirazol, processo para sua preparação e uso dos mesmos como agentes antitumorais |
| CA2318004A1 (en) | 1999-09-15 | 2001-03-15 | Oridigm Corporation | Novel polyamine analogues as therapeutic and diagnostic agents |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
-
1999
- 1999-01-26 GB GBGB9901691.7A patent/GB9901691D0/en not_active Ceased
-
2000
- 2000-01-26 AU AU21169/00A patent/AU2116900A/en not_active Abandoned
- 2000-01-26 AT AT00901207T patent/ATE262326T1/de not_active IP Right Cessation
- 2000-01-26 ES ES00901207T patent/ES2216852T3/es not_active Expired - Lifetime
- 2000-01-26 CA CA002360674A patent/CA2360674A1/en not_active Abandoned
- 2000-01-26 EP EP00901207A patent/EP1143964B1/en not_active Expired - Lifetime
- 2000-01-26 WO PCT/GB2000/000207 patent/WO2000044371A1/en not_active Ceased
- 2000-01-26 US US09/890,061 patent/US6531511B1/en not_active Expired - Fee Related
- 2000-01-26 DE DE60009263T patent/DE60009263T2/de not_active Expired - Fee Related
- 2000-01-26 JP JP2000595674A patent/JP2002535360A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2373653C (en) | New use of compounds as antibacterial agents | |
| JP2003500442A5 (enExample) | ||
| JP2001526218A5 (enExample) | ||
| JP2002513793A5 (enExample) | ||
| JP2004517087A5 (enExample) | ||
| JP2004532209A5 (enExample) | ||
| JP2005502635A5 (enExample) | ||
| JP2002543121A5 (enExample) | ||
| JP2004536115A5 (enExample) | ||
| JP2002030084A5 (enExample) | ||
| JP2002518502A5 (enExample) | ||
| JP2002527414A5 (enExample) | ||
| JP2003503449A5 (enExample) | ||
| JP2005526696A5 (enExample) | ||
| KR960701007A (ko) | 피롤-아미딘계 화합물 및 약제학적으로 허용 가능한 그 염, 그 제조방법 및 상기 화합물을 포함하는 약제조성물 | |
| JP2005505583A5 (enExample) | ||
| JP2004521150A5 (enExample) | ||
| JP2002535360A5 (enExample) | ||
| JP2007515467A5 (enExample) | ||
| JP2003518022A5 (enExample) | ||
| JP2002526530A5 (enExample) | ||
| JP2003522741A5 (enExample) | ||
| JP2002539089A5 (enExample) | ||
| CA2499721A1 (en) | Chirale oxazole-arylpropionic acid derivatives and their use as ppar agonists | |
| JP2002514623A5 (enExample) |